GlassScriptPhysician profile
James H Rubright
NPI 1003031261
$768.48
in general payments reported to CMS, 2019-2025
13 companies · $92.00 in 2025
The $92.00 reported for 2025 was less than what a typical Hand Surgery provider received nationally (typical 2025 total: $270).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $28.87 · 2021: $28.98 · 2022: $172 · 2024: $247 · 2025: $92.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $181 · Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $181.16 |
| Food and Beverage | $158.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $181.16 | 2024 | Integra |
| Stryker Corporation | $125.36 | 2019-2025 | 1788 |
| Endo Pharmaceuticals INC. | $120.23 | 2019-2022 | |
| Orthofix Medical, INC. | $62.83 | 2019-2022 | |
| Endo USA, INC. | $54.65 | 2024-2025 | Xiaflex |
| Smith+Nephew, INC. | $42.88 | 2020-2024 | Bioinductive Implant With Arthroscopic Delivery System - Medium, Healicoil |
| Alpha Orthopedic Systems | $40.24 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $37.00 | 2025 | Iovera, Zilretta |
| Davol INC. | $31.89 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $20.31 | 2022 | |
| Axogen | $19.59 | 2022 | |
| Kerecis Limited | $17.87 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Acumed LLC | $14.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rubright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.